Cipla Q2FY22, PAT rises 7% YoY to Rs 711 crore, beats estimates The drug maker's sales increased 9.56% to Rs 5519.80 crore in Q2 FY22 as compared to Rs 5038.29 reported in Q2 FY21. Its profit before tax increased 7.5% to Rs 995.81 crore in Q2 FY22 as compared to Rs 925.65 reported in Q2 FY21. EBITDA rose 4% year on year to Rs 1,226 crore in Q2 FY22. EBITDA margin for Q2 FY22 stood at 22.2% as compared to 23.4% posted in Q2 FY21. R&D; investments stood at Rs 274 crore in Q2 FY22 with priority projects spends on track....